{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:56:00Z","timestamp":1793832960087,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biocompatibles UK LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC). First-line DEBIRI with systemic chemotherapy may increase survival and secondary resection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the FFCD-1201 single-arm Phase 2 study, patients with untreated, non-resectable LMCRC received DEBIRI plus mFOLFOX6. Four courses of DEBIRI were performed alternating right and left lobe or two sessions with both lobes treated during the same session.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-seven patients were enrolled. Grade 3\u20135 toxicities were more frequent when both lobes were treated during the same session (90.5% versus 52.8%). Nine-month PFS rate was 53.6% (95% CI, 41.8\u201365.1%). The objective response rate (RECIST 1.1) was 73.2%, and the secondary R0 surgery was 33%. With a median follow-up of 38.3 months, median OS was 37.4 months (95% CI, 25.7\u201345.8), and median PFS 10.8 months (95% CI, 8.2\u201312.3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Front-line DEBIRI\u2009+\u2009mFOLFOX6 should not be recommended as the hypothesised 9-month PFS was not met. However, high response rate, deep responses, and prolonged OS encourage further evaluation in strategies integrating biologic agent, in particular in patients with secondary surgery as the main goal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>NCT01839877.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0917-4","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T23:02:53Z","timestamp":1591570973000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-585X","authenticated-orcid":false,"given":"Simon","family":"Pernot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Artru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Mont\u00e9rymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"Christelle","family":"De La Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for FFCD1201-DEBIRI investigators\/Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"917_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670\u20131676 (2007).","journal-title":"J. Clin. Oncol."},{"key":"917_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"J Souglakos","year":"2006","unstructured":"Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A. et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer 94, 798\u2013805 (2006).","journal-title":"Br. J. Cancer"},{"key":"917_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306\u20131315 (2015).","journal-title":"Lancet Oncol."},{"key":"917_CR4","first-page":"CD009498","volume":"4","author":"RP Riemsma","year":"2013","unstructured":"Riemsma, R. P., Bala, M. M., Wolff, R. & Kleijnen, J. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst. Rev. 4, CD009498 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"917_CR5","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ejso.2016.07.142","volume":"42","author":"RP Jones","year":"2016","unstructured":"Jones, R. P., Malik, H. Z., Fenwick, S. W., Terlizzo, M., O\u2019Grady, E., Stremitzer, S. et al. PARAGON II - a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur. J. Surg. Oncol. 42, 1866\u20131872 (2016).","journal-title":"Eur. J. Surg. Oncol."},{"key":"917_CR6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","volume":"17","author":"R Adam","year":"2012","unstructured":"Adam, R., Gramont, A. D., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F. et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17, 1225\u20131239 (2012).","journal-title":"Oncologist"},{"key":"917_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1245\/s10434-013-3275-0","volume":"21","author":"A Cercek","year":"2014","unstructured":"Cercek, A., D\u2019Angelica, M., Power, D., Capanu, M., Gewirtz, A., Patel, D. et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann. Surg. Oncol. 21, 479\u2013486 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"917_CR8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J. et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 18, 1159\u20131171 (2017).","journal-title":"Lancet Oncol."},{"key":"917_CR9","doi-asserted-by":"publisher","first-page":"28716","DOI":"10.18632\/oncotarget.4747","volume":"6","author":"G Aprile","year":"2015","unstructured":"Aprile, G., Fontanella, C., Bonotto, M., Rihawi, K., Lutrino, S. E., Ferrari, L. et al. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 6, 28716\u201328730 (2015).","journal-title":"Oncotarget"},{"key":"917_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s11605-012-1892-8","volume":"16","author":"RCG Martin","year":"2012","unstructured":"Martin, R. C. G., Scoggins, C. R., Tomalty, D., Schreeder, M., Metzger, T., Tatum, C. et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J. Gastrointest. Surg. 16, 1531\u20131538 (2012).","journal-title":"J. Gastrointest. Surg."},{"key":"917_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004). 2004.","journal-title":"N. Engl. J. Med."},{"key":"917_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065\u20131075 (2014).","journal-title":"Lancet Oncol."},{"key":"917_CR13","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392\u20132401 (2017).","journal-title":"JAMA"},{"key":"917_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/annonc\/mdu580","volume":"26","author":"T Gruenberger","year":"2015","unstructured":"Gruenberger, T., Bridgewater, J., Chau, I., Garc\u00eda Alfonso, P., Rivoire, M., Mudan, S. et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann. Oncol. 26, 702\u2013708 (2015).","journal-title":"Ann. Oncol."},{"key":"917_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2017.10.028","volume":"88","author":"DP Modest","year":"2018","unstructured":"Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M. et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer\u2014central evaluation of FIRE-3. Eur. J. Cancer 88, 77\u201386 (2018).","journal-title":"Eur. J. Cancer"},{"key":"917_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer, C., Van Cutsem, E., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48, 1466\u20131475 (2012).","journal-title":"Eur. J. Cancer"},{"key":"917_CR17","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/annonc\/mdq714","volume":"22","author":"R Wong","year":"2011","unstructured":"Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T. et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann. Oncol. 22, 2042\u20132048 (2011).","journal-title":"Ann. Oncol."},{"key":"917_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4254\/wjh.v11.i2.150","volume":"11","author":"FC-L Chow","year":"2019","unstructured":"Chow, F. C.-L. & Chok, K. S.-H. Colorectal liver metastases: an update on multidisciplinary approach. World J. Hepatol. 11, 150\u2013172 (2019).","journal-title":"World J. Hepatol."},{"key":"917_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejso.2017.11.006","volume":"44","author":"K Omichi","year":"2018","unstructured":"Omichi, K., Shindoh, J., Cloyd, J. M., Mizuno, T., Chun, Y. S., Conrad, C. et al. Liver resection is justified for patients with bilateral multiple colorectal liver metastases: a propensity-score-matched analysis. Eur. J. Surg. Oncol. 44, 122\u2013129 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"917_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1055-3207(02)00091-1","volume":"12","author":"A Altendorf-Hofmann","year":"2003","unstructured":"Altendorf-Hofmann, A. & Scheele, J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. North Am. 12, 165\u2013192 (2003).","journal-title":"Surg. Oncol. Clin. North Am."},{"key":"917_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/bjs.4071","volume":"90","author":"D Elias","year":"2003","unstructured":"Elias, D., Ouellet, J.-F., Bellon, N., Pignon, J.-P., Pocard, M. & Lasser, P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br. J. Surg. 90, 567\u2013574 (2003).","journal-title":"Br. J. Surg."},{"key":"917_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1056\/NEJMra065156","volume":"356","author":"P-A Clavien","year":"2007","unstructured":"Clavien, P.-A., Petrowsky, H., DeOliveira, M. L. & Graf, R. Strategies for safer liver surgery and partial liver transplantation. N. Engl. J. Med. 356, 1545\u20131559 (2007).","journal-title":"N. Engl. J. Med."},{"key":"917_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11, 38\u201347 (2010).","journal-title":"Lancet Oncol."},{"key":"917_CR24","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","volume":"27","author":"NE Kemeny","year":"2009","unstructured":"Kemeny, N. E., Melendez, F. D. H., Capanu, M., Paty, P. B., Fong, Y., Schwartz, L. H. et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 27, 3465\u20133471 (2009).","journal-title":"J. Clin. Oncol."},{"key":"917_CR25","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/cncr.29534","volume":"121","author":"RCG Martin","year":"2015","unstructured":"Martin, R. C. G., Scoggins, C. R., Schreeder, M., Rilling, W. S., Laing, C. J., Tatum, C. M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 121, 3649\u20133658 (2015).","journal-title":"Cancer"},{"key":"917_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jso.24141","volume":"113","author":"O Akinwande","year":"2016","unstructured":"Akinwande, O., Philips, P., Scoggins, C. R., Kelly, L., Tatum, C., Hahl, M. et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J. Surg. Oncol. 113, 443\u2013448 (2016).","journal-title":"J. Surg. Oncol."},{"key":"917_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.suronc.2017.05.003","volume":"26","author":"O Akinwande","year":"2017","unstructured":"Akinwande, O., Dendy, M., Ludwig, J. M. & Kim, H. S. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surg. Oncol. 26, 268\u2013275 (2017).","journal-title":"Surg. Oncol."},{"key":"917_CR28","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s00330-018-5967-0","volume":"29","author":"L-J Palmieri","year":"2019","unstructured":"Palmieri, L.-J., Fihri, A., Doat, S., Dubreuil, O., Manceau, G., Karoui, M. et al. Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. Eur. Radiol. 29, 3871\u20133880 (2019).","journal-title":"Eur. Radiol."},{"key":"917_CR29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00270-010-9937-4","volume":"33","author":"RCG Martin","year":"2010","unstructured":"Martin, R. C. G., Howard, J., Tomalty, D., Robbins, K., Padr, R., Bosnjakovic, P. M. et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc. Intervent. Radiol. 33, 960\u2013966 (2010).","journal-title":"Cardiovasc. Intervent. Radiol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0917-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0917-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0917-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:08:51Z","timestamp":1684616931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0917-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8,18]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0917-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"2 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This multi-centre, single-arm, Phase 2 study was approved by the French ethics committee \u201cCPP Ile de France 8\u201d (committee\u2019s reference No. 1212113). All patients provided informed consent before study enrolment. The study was performed in accordance with the declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not include any person\u2019s individual data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}},{"value":"Data can be found based on reasonable demand to the promoter \u201cF\u00e9d\u00e9ration Fran\u00e7aise de Canc\u00e9rologie digestive (FFCD)\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"S.P. has received honoraria as a speaker and\/or advisor from Sanofi, Amgen, and Servier. O.P. has received honoraria as a speaker and\/or advisor from Merit Medical and COGITh-SAS. J.T. has received honoraria as a speaker and\/or advisor from Merck KGaA, Sanofi, Roche Genentech, MSD, Lilly, Celgene, Servier, Pierre Fabre, and Amgen. J.-L.R. has received honoraria for speaker\/advisory role from Astra Zeneca, Bayer, BTG, Ipsen, and Merck. D.T. has received honoraria for speaker or\/and advisory role from Merck KGaA, Sanofi, Roche Genentech, MSD, Novartis, BMS, Servier, Bayer, and Amgen; D.S. has received honoraria for speaker or\/and advisory role from Amgen, Ipsen, and Servier. C.D.L.F. has received honoraria for speaker\/advisory role from Servier, Roche Genentech, MSD, Lilly, Celgene, Pierre Fabre, and Amgen. R.G. has received honoraria for speaker\/advisory role from Pierre Fabre, Astra Zeneca, Amgen, Servier, and Novartis. All the remaining authors have declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported, and product provided free of charge, by Biocompatibles UK Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}